MedPath

Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images

Recruiting
Conditions
Nasopharyngeal Carcinoma
Image-Guided Biopsy
Registration Number
NCT05202626
Lead Sponsor
Chinese Academy of Sciences
Brief Summary

Due to the occult anatomic location of the nasopharynx and frequent presence of adenoid hyperplasia, the positive rate for nasopharyngeal carcinoma identification during biopsy is low, thus leading to delayed or missed diagnosis for nasopharyngeal carcinoma upon initial attempt. Here, we aimed to develop an artificial intelligence tool to detect nasopharyngeal malignancies and guide biopsy under endoscopic examination based on deep learning.

Detailed Description

Due to the occult anatomic location of the nasopharynx and frequent presence of adenoid hyperplasia, the positive rate for nasopharyngeal carcinoma identification during biopsy is low, thus leading to delayed or missed diagnosis for nasopharyngeal carcinoma upon initial attempt. Here, we aimed to develop an artificial intelligence tool to detect nasopharyngeal malignancies and guide biopsy under endoscopic examination based on deep learning.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • The patient was found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy and the clinicans considered it necessary to perform an biopsy.
  • Hemilateral lesion with limited size.
Exclusion Criteria
  • Patients with nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, etc. who have already been treated.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Aera under the receiver operating characteristic curve (AUC)three months

AUC of an deep learning-based model in discriminating nasopharyngeal carcinoma from bengin lesion.

Secondary Outcome Measures
NameTimeMethod
Accuraythree months

The agreement between the deep learning-based model and the histopathological diagnosis of the three biopsy specimens (inside the lesion, 5-8 mm outside the lesion, and 8-10 mm outside the lesion).

Trial Locations

Locations (5)

Fujian Provincial Cancer Hospital

🇨🇳

Fuzhou, Fujian, China

Guangdong Provincial People's Hospital

🇨🇳

Guangzhou, Guangdong, China

Nanfang Hospital, Southern Medical University

🇨🇳

Guangzhou, Guangdong, China

Sun Yat-Sen University Cancer Center

🇨🇳

Guangzhou, Guangdong, China

Hainan Provincial People's Hospital

🇨🇳

Haikou, Hainan, China

Fujian Provincial Cancer Hospital
🇨🇳Fuzhou, Fujian, China
Sufang Qiu
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.